E-Healthcare Solutions (EHS) announced that Ascend Media Healthcare has signed an exclusive representation agreement that names EHS as the sole provider of on-line advertising for Ascend Media’s Healthcare portfolio of medical and healthcare websites. The agreement calls for EHS to centrally sell and deliver advertising campaigns to the online publications in the healthcare division, including Cardiology Review, The American Journal of Managed Care, Pharmacy Times, Internal Medicine World Report, Physician’s Money Digest, Surgical Rounds, Family Practice Recertification and Resident & Staff Physician.
Bayer HealthCare Pharmaceuticals , a US-based pharmaceuticals unit of Bayer HealthCare, and Intendis , a US-based affiliate of Bayer Schering Pharma AG, Germany, announced that they will jointly promote Yaz (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control. The agreement went into effect on May 1, as part of an overall strategy to introduce dermatologists to the anti-acne benefits of Yaz. Investigators will present new clinical data demonstrating the efficacy of Yaz in the treatment of moderate acne at the American College of Obstetricians and Gynecologists (ACOG) annual clinical meeting in San Diego. Yaz is the only oral contraceptive approved for the treatment of premenstrual dysphoric disorder (PMDD) in women who desire an oral contraceptive for birth control. PMDD is a condition in which women's premenstrual symptoms are severe enough to impact activities, work or relationships. In January, 2007, Yaz received FDA approval as a treatment for moderate acne in women who desire an oral contraceptive for birth control.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.